Posted on 12/10/19

Catalyst Pharmaceuticals: A Potential Double In 2020

SummaryFirdapse is expected to be approved outside the U.S.Profitability is expected this year, and the P/E is only about 4.6.Catalyst's lawsuit against the FDA has a . . .